KM
JAZZ icon

Kalos Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kalos Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,341
Closed -$978K – 251
2021
Q4 		$978K Buy
7,341
+282
+4% +$37.1K 0.26% 92
2021
Q3 		$941K Sell
7,059
-442
-6% -$66.8K 0.27% 92
2021
Q2 		$1.13M Buy
7,501
+185
+3% +$32K 0.46% 68
2021
Q1 		$1.27M Sell
7,316
-231
-3% -$38K 0.4% 75
2020
Q4 		$1.26M Sell
7,547
-54
-0.7% -$8.04K 0.54% 62
2020
Q3 		$1.14M Buy
7,601
+41
+0.5% +$5.08K 0.51% 63
2020
Q2 		$927K Sell
7,560
-150
-2% -$16.6K 0.39% 84
2020
Q1 		$881K Buy
+7,710
New +$997K 0.39% 80
2015
Q4 		– Hold
0
– – – 323

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Kalos Management's JAZZ Position: Q1 2022 in Review

Kalos Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 7,341 shares — an estimated $978K sold.

Kalos Management first reported a position in JAZZ in Q1 2020 and held it in 8 quarters. The position peaked at $1.27M in Q1 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

  • Kalos Management reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Kalos Management sold 7,341 Jazz Pharmaceuticals shares in Q1 2022, an estimated $978K.
  • Kalos Management first reported a position in Jazz Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • Kalos Management's Jazz Pharmaceuticals position peaked at $1.27M in Q1 2021.
  • 462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Kalos Management's 13F filing for Q1 2022, filed 21 Jun 2022.